Clinical Trial Update: A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia [Phase 3]

View source ↗

Summary

Phase III trial update for PA21 with calcium carbonate in hemodialysis patients with hyperphosphatemia; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• PA21 with calcium carbonate

Snippet

Sponsor: Kissei Pharmaceutical Co., Ltd. | Conditions: Hemodialysis, Hyperphosphatemia | Phase 3 | Status: COMPLETED | Results posted: 2018-10-09